CVS Health (CVS) call put ratio 1.3 calls to 1 put into quarter results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
CVS Health (CVS) PT Lowered to $63 at Deutsche Bank
August 8, 2024 12:31 PM EDTDeutsche Bank analyst George Hill lowered the price target on CVS Health (NYSE: CVS) to $63.00 (from $64.00) while maintaining a Hold rating.
The analyst comments "The Tumult Reaches a New High, as Guidance Reaches a New Low: CVS reported Q2 results and provided an updated earnings outlook with a... More
CVS Health (CVS) cuts full-year EPS guidance on continued pressure in the health care benefits unit
August 7, 2024 6:45 AM EDT(Updated - August 7, 2024 9:56 AM EDT)
CVS Health (NYSE: CVS) reported second-quarter earnings that beat analyst expectations, but shares fell by more than 2% as the company cut its full-year guidance, citing continued pressure in its Health Care Benefits segment.
The healthcare giant reported adjusted earnings per share (EPS) of $1.83 for Q2, surpassing the analyst estimate of $1.73. However, revenue came in at $91.2 billion, slightly below the consensus estimate of $91.43 billion, though it represented a 2.6% increase YoY.
CVS Health revised its full-year 2024 adjusted EPS guidance to a range of $6.40 to $6.65, down from its... More
